science
Eli Lilly to Acquire AtaiBeckley for $2.8 Billion Upfront
Eli Lilly will pay $2.8 billion in cash to acquire AtaiBeckley, a developer of psychedelic treatments for mental health conditions. The deal includes up to $1 billion in additional milestone payments. It adds the target’s compounds to Lilly’s neuroscience programs.
Jul 16, 10:15 AM·1m read4 sources
YA+2
indianexpress.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Eli Lilly agreed on July 16 to acquire AtaiBeckley for $2.8 billion in cash upfront. The agreement includes up to an additional $1 billion tied to development and regulatory milestones, bringing the potential total value to $3.8 billion. The acquisition will add AtaiBeckley’s pipeline of psychedelic compounds to Lilly’s existing neuroscience programs.
AtaiBeckley develops psychedelic treatments for mental health conditions. Lilly stated the purchase continues a series of recent acquisitions made possible by cash generated from its GLP-1 weight-loss and diabetes medicines. No regulatory approvals or closing timeline were detailed.
The transaction remains subject to customary closing conditions.
Transparency
How sources framed this
These outlets didn't split into competing frames — coverage was uniform.
CorroborationModerate · 4 sources
